Trastuzumab Deruxtecan

What Trastuzumab Deruxtecan Means in Everyday Medical Language

Trastuzumab deruxtecan, often called Enhertu, is a cancer medicine that targets tumors with a protein called HER2 on their cells. It is a special type of drug known as an antibody-drug conjugate. This means it combines two parts: a monoclonal antibody named trastuzumab that finds and sticks to HER2 proteins on cancer cells, and a chemotherapy drug called deruxtecan that is carried directly into those cells. Once inside, deruxtecan damages the cancer cells’ DNA, helping to kill them. This targeted approach aims to focus treatment on cancer cells while limiting harm to normal cells.

Why Trastuzumab Deruxtecan Can Matter in Cancer Care

Enhertu offers a treatment option for adults with certain HER2-positive or HER2-low cancers that are difficult to treat. These include breast cancer that cannot be removed by surgery or has spread, stomach or gastroesophageal junction cancers, and some lung cancers with specific HER2 gene changes. It is often used when other treatments have not worked or when cancer has returned. Enhertu was the first targeted therapy approved for HER2-low breast cancer, expanding options for patients with this subtype. Because it targets HER2, it can be more effective for cancers that rely on this protein to grow.

What Patients Might See, Feel, or Be Told About Trastuzumab Deruxtecan

If Enhertu is mentioned in your care, you might hear it called by its brand name or by other names like fam-trastuzumab deruxtecan or trastuzumab deruxtecan. Your healthcare team may explain that it is a targeted therapy designed to attack cancer cells with HER2. You might be told about the treatment schedule, possible side effects such as nausea, tiredness, hair loss, or lung problems, and the need for regular check-ups during treatment. Because it can cause lung inflammation, close monitoring is important. You may also see information about clinical trials studying Enhertu for other cancers or new uses.

Where Trastuzumab Deruxtecan Might Appear in Your Care

Enhertu can appear in your medical records, treatment plans, or test results under any of its names. It may also be listed on clinical trial pages if you are considering research studies. Drug information sheets or patient guides from your healthcare team or pharmacy will provide details about how it works, how to take it, and what side effects to watch for. Recognizing its different names can help you understand your care better.

What Trastuzumab Deruxtecan Does Not Automatically Mean

Seeing the name Enhertu or trastuzumab deruxtecan does not mean it is the right treatment for every HER2-positive cancer or that it will work for all patients. It is specifically approved for certain types and stages of cancer, often after other treatments. Also, HER2-low cancers are different from HER2-positive cancers, and Enhertu’s approval for HER2-low breast cancer is a newer development. Enhertu is not a cure but a treatment option that may help control cancer. Side effects can be serious, so it is important to discuss risks and benefits with your care team.

Safety and Next Steps

This information is meant to help you understand what trastuzumab deruxtecan is and how it might be used. It is not a substitute for medical advice. If you see this term in your medical records or hear it from your healthcare team, the best next step is to ask them what it means for your specific situation. They can explain if this treatment is appropriate for you, what to expect, and how to manage side effects. Always share any symptoms or concerns during treatment so your care team can support you safely.